IE
BIOSU

Israel Englander’s BioPlus Acquisition Corp. Unit BIOSU Stock Holding History

Israel Englander’s Portfolio BIOSU Stock Details BIOSU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-135,000
Closed -$1.35M – 7722
2022
Q1 		$1.35M Hold
135,000
– – ﹤0.01% 4246
2021
Q4 		$1.35M Buy
+135,000
New +$1.35M ﹤0.01% 4126

Other funds holding BIOSU

Calamos Advisors
Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $507M AUM 6.15% 1-Year Est. Return
ACM
Atalaya Capital Management New York $45M AUM 3.02% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
WC
Wealthspring Capital West Harrison, New York $448M AUM 8.38% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
SFM
Spartan Fund Management Toronto, Ontario, Canada $30M AUM 11.98% 1-Year Est. Return
SIA
Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return
FLC
Fifth Lane Capital Austin, Texas $1.63M AUM 7.3% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return

Israel Englander's BIOSU Position: Q2 2022 in Review

Israel Englander sold out of BioPlus Acquisition Corp. Unit (BIOSU) in Q2 2022, closing a stake of 135,000 shares — an estimated $1.35M sold.

Israel Englander first reported a position in BIOSU in Q4 2021 and held it in 2 quarters. The position peaked at $1.35M in Q4 2021. 24 funds tracked by Wall St. Rank hold BIOSU as of Q2 2022.

  • Israel Englander reported no remaining BioPlus Acquisition Corp. Unit position as of Q2 2022 after selling out during the quarter.
  • Israel Englander sold 135,000 BioPlus Acquisition Corp. Unit shares in Q2 2022, an estimated $1.35M.
  • Israel Englander first reported a position in BioPlus Acquisition Corp. Unit in Q4 2021 and held it in 2 quarters.
  • Israel Englander's BioPlus Acquisition Corp. Unit position peaked at $1.35M in Q4 2021.
  • 24 funds tracked by Wall St. Rank held BioPlus Acquisition Corp. Unit as of Q2 2022.

Based on Millennium Management's 13F filing for Q2 2022, filed 15 Aug 2022.